Clinical Trial Update: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing acalabrutinib (ACP-196) to ibrutinib in previously treated high-risk chronic lymphocytic leukemia; status is active not recruiting with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-01-28